Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Boulogne-Billancourt – page 48

3 430 clinical trials in Boulogne-Billancourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Boulogne-Billancourt at a glance
3 430
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 430 trials in Boulogne-Billancourt

Open in trial search

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LY3372993
  • Sponsor:Washington University School Of Medicine

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Prednisolone Acetate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Early Treatment with Argipressin (Arginine Vasopressin) in Adult Intensive Care Patients with Norepinephrine-Resistant Vasoplegic Shock

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Boulogne-Billancourt

What the registry says about research in the country

01 Lung Cancer Research

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) and novel treatment approaches, including immunotherapy combinations and targeted therapies.

  • Advanced stage treatment evaluation
  • Immunotherapy effectiveness
  • Combination therapy assessment

Studies investigating various treatment strategies for both elderly patients and those with specific genetic mutations.

02 Melanoma Studies

Research centered on advanced melanoma treatment, particularly in high-risk stages and post-surgical care.

  • Adjuvant therapy trials
  • Stage III melanoma management
  • Immunotherapy protocols

Focus on improving survival rates through targeted therapeutic approaches and immune system modulation.

03 Kidney and Cardiovascular Research

Investigations into chronic kidney disease (CKD) treatment and cardiac conditions, including innovative therapeutic combinations.

  • Blood pressure management
  • Cardiac function improvement
  • Disease progression prevention

Studies evaluating new treatment approaches for patients with complex cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.